Press release

Medios AG achieves strong growth in earnings and profit margin in the first nine months of 2025

• Revenue increases by 9.2% to €1,530.0 million
• Disproportionately high EBITDA pre¹ increase of 26.1%
• Organic EBITDA pre¹ growth of 5.1%
• Cash flow from operating activities almost doubles
• Significant improvement in earnings per share to €0.79
• New CEO Thomas Meier to take office on February 1, 2026
• Outlook for 2025 confirmed

Berlin, November 11, 2025 – The Medios-Group (“Medios“ or “the Company”), a leading provider of Specialty Pharma in Europe, once again delivered strong performance in the period from January to September 2025 and confirms its forecast for the full year. Revenue rose by 9.2% to €1,530.0 million in the nine-month period (9M). EBITDA pre¹ rose again disproportionately by 26.1% to €70.4 million. Organic EBITDA pre¹ growth amounted to 5.1%. As a result, the EBITDA pre¹ margin improved by 0.6 percentage points to 4.6%. Consolidated net income after taxes nearly doubled to €19.9 million (9M 2024: €10.4 million). Earnings per share thus rose to €0.79 (9M 2024: €0.43). Cash flow from operating activities also increased significantly to €52.7 million (9M 2024: €27.6 million).

Matthias Gärtner, CEO of Medios AG, stated: “We are very pleased with the current business performance. In the third quarter, we not only achieved a significant increase in revenue to around €538 million, but also our earnings of €24 million were very close to the record figure of €24.6 million in the same quarter of the previous year, which was characterized by a positive one-off effect due to inflation. Over the first nine months, we recorded strong growth and further improved all key figures. This successful development once again reflects the consistent execution of our growth strategy.”

Revenue and earnings growth in all operating segments
The Pharmaceutical Supply business segment achieved a 4.1% increase in revenue to €1,239.5 million in the first nine months of 2025. EBITDA pre¹ rose by 4.7% to €38.8 million, mainly as a result of organic earnings growth due to the strategic focus on higher-margin revenue.

The Patient-Specific Therapies business segment recorded a 2.7% increase in revenue to €166.0 million from January to September 2025. The segment’s EBITDA pre¹ rose by 8.4% to €18.1 million, reflecting strong organic growth and a further optimized product mix.

The International Business division generated revenue of €124.2 million in the nine-month period 2025 (June to September 2024: €47.3 million). The division contributed €22.0 million to EBITDA pre¹ (June to September 2024: €9.8 million).

New CEO to take office on February 1, 2026
The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and named him as the new Chief Executive Officer (CEO) of the company. He succeeds Matthias Gärtner, who will remain in office until December 31, 2025.

Outlook for 2025 confirmed
Medios confirms its forecast for the 2025 financial year. The company expects sales revenue to increase by around 6% to approximately €2 billion. EBITDA pre¹ is expected to rise disproportionately by around 21.5% to approximately €96 million. This corresponds to a further increase in the EBITDA pre¹ margin to around 4.8%. This expectation is based on the assumption of organic growth in the mid-single-digit percentage range and takes into account the consolidation of the Ceban Group for twelve months.

The Quarterly Statement of Medios AG as of September 30, 2025 is available for download on the Investor Relations website.

Important dates for Medios AG in the 2025 financial year

——————-

About Medios AG
Medios is a leading provider of Specialty Pharma in Europe. With locations in Germany, the Netherlands, Belgium and Spain, the Company supports key partners in the supply chain with innovative solutions and intelligent services. Medios has focused on pioneering individualized medicine to make the most innovative therapies available to everyone together with pharmacies, specialist practices and pharmaceutical companies.

Medios AG is Germany’s first listed specialty pharmaceutical Company. The shares (ISIN: DE000A1MMCC8) are listed on the regulated market of the Frankfurt Stock Exchange (Prime Standard) and are included in the SDAX selection index.

www.medios.group

More information on individualized medicine: https://app.medios.group/en/individualizedmedicine

Contact
Claudia Nickolaus
Head of Investor & Public Relations, ESG Communications
Medios AG
Heidestraße 9 | 10557 Berlin
T +49 30 232 566 800
ir@medios.group
www.medios.ag

Disclaimer
This communication contains forward-looking statements that are subject to certain risks and uncertainties. Future results could differ materially from those currently anticipated as a result of various risk factors and uncertainties, including, but not limited to, changes in business, economic and competitive conditions, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Medios AG assumes no responsibility to update any forward-looking statements contained in this release.